To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

NCT04515927 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Hyperlipemia

Interventions

DRUG: JS002

Sponsor

Shanghai Junshi Bioscience Co., Ltd.